Thanks for the reply. I may be inclined to agree in regards to the test's veterinary potential. I am not familiar with animal biology to the point of FDP level intimacy so I can't make a firm decision.
However, as far as CRC monitoring is concerned, in my opinion, Onko-Sure just needs three things: 1) Good Mayo results, 2) Good marketing, and 3) Supply. Furthermore, I believe, even if the latter two aren't in place, there will be a domino effect for them to be in place. If good Mayo results are announced then it will follow that good marketing will get the word out of the superior product. When orders are placed, supply can easily be produced with the clean sheet resultant of the D/E. Do you see a hiccup at any of these points? Or do you simply believe that CEA is a better product despite its similar numbers and lack of early stage benefit?
